有趣的是，Infigratinib最初于2021年获批用于胆管癌，后因适应症开发策略调整而主动撤回。如今，其有望在ACH赛道迎来“第二春”。基于其疗效和口服便利性，BridgeBio在今年的JPM大会上预测，该药Infigratinib将占据ACH治疗市场50%以上的份额。
ITmedia�̓A�C�e�B���f�B�A�������Ђ̓o�^���W�ł��B
，详情可参考heLLoword翻译官方下载
Allow TikTok content?This article contains content provided by TikTok. We ask for your permission before anything is loaded, as they may be using cookies and other technologies. You may want to read TikTok’s cookie policy。旺商聊官方下载对此有专业解读
'We have a new major number purely because I'm easily confused and not good with big numbers' says Linus Torvalds about Linux 7.0